This week, 11 new stocks were subscribed, 2 were pharmaceutical new stocks!

【Pharmaceutical Network Pharmaceutical Stock Market】According to the statistics of Flush, this week (September 5 to September 9) a total of 11 new stocks were subscribed, including Kejie Intelligent, Enwei Pharmaceutical, Wonder Kai, Huabao New Energy, Tin Packaging Shares, Zhejiang Zhengte, Jiebang Technology, Pava Shares, Debon Technology, Magnetic Valley Technology, Nuocheng Jianhua, etc.
, of which Enwei Pharmaceutical and Nuocheng Jianhua are two pharmaceutical new stocks
.

Enwei Pharmaceutical: Online subscription on September 6 Among them, Enwei Pharmaceutical disclosed the company's initial public offering of shares on the evening of September 4 and listed on the ChiNext board, saying that the number of shares in the public offering was 17.
54 million shares, and the issue price was 29.
8 yuan / share; Online subscription will be made on September 6, 2022
.

The total amount of funds raised by the issuer is expected to be approximately $
523 million.

Enwei Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines and chemical drugs, focusing on gynecological products, pediatric drugs, respiratory drugs and other fields
.

The company's main products are OTC drugs
.

Since its inception, the company has continuously improved the coverage capacity of terminal retail pharmacies, and the number of pharmacies maintained by its own team has reached more than 60,000
.

The report shows that in the past three years, the company's main business income and net profit attributable to the mother after deduction of non-deduction have maintained sustained and steady growth, of which the compound growth rate of the company's main business income from 2019 to 2021 is 4.
78%, and the compound growth rate of the company's net profit after deduction of non-attributable to the mother is 9.
65%.


From January to June 2022, the company's operating income was 334.
7819 million yuan, the net profit attributable to the shareholders of the parent company was 39.
1871 million yuan, and the net profit attributable to the shareholders of the parent company after deducting non-recurring gains and losses was 36.
6823 million yuan, and the net profit fell slightly year-on-year, mainly due to
the increase in raw material costs.

With the continuous expansion of the company's product line, the company's comprehensive gross profit margin has also increased steadily in the past three years, and the company's net profit margin on sales is 14.
75%, 16.
59% and 14.
97%, respectively, reflecting strong profitability
.

In addition, during the reporting period, the total investment of the issuer related to R&D and technological upgrading and innovation accounted for 2.
48%, 3.
20% and 3.
48% of the operating income, respectively, showing an upward trend
year by year.

Nuocheng Jianhua: On September 9, Nuocheng Jianhua will start online new shares of the science and technology innovation board, Nuocheng Jianhua will start online new on September 9, it is worth mentioning that as early as March 2020, Nuocheng Jianhua has been listed on the Hong Kong Stock Exchange, and if it can successfully land on A shares, it means that the company will achieve A+ H listing
.

As an innovative biomedical company, Nuocheng Jianhua mainly focuses on areas with huge unmet clinical needs such as tumors and autoimmune diseases, and develops best-in-class or first-of-its-kind drugs
with breakthrough potential in the global market.

At present, one of the company's main products, obutinib (Enokai ®), has been conditionally approved by the State Food and Drug Administration for listing in December 2020, Tafasitamab has been approved to be used as a clinically urgently needed imported drug in Boao Super Hospital, 11 products are in the phase I/II/III clinical trial stage, and 5 products are in the pre-clinical stage
.

From the performance point of view, the company's revenue from 2020 to the first half of 2022 was 1.
3636 million yuan, 1.
043 billion yuan and 246 million yuan, and the net profit was -391 million yuan, -64.
546 million yuan and -441 million yuan
, respectively.

At present, the company has not achieved profitability
.

In addition, according to the company's prospectus, as of December 31, 2021, Hillhouse's HHLR directly held 199 million shares of the company, accounting for 13.
30% of the total number of issued shares of the company, and was the largest shareholder of the company; HHLR and its co-actor YHG16 hold a total of 208 million shares in the Company, representing 13.
85%
of the total number of issued shares in the Company.

It is reported that the company plans to raise 4 billion yuan in this IPO, of which 2.
15 billion yuan is used for new drug research and development projects; 167 million yuan is used for drug research and development platform upgrade projects; 394 million yuan is used for marketing network construction projects; 87.
7385 million yuan is used for information construction projects; and 1.
2 billion yuan is used to supplement working capital
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.